Home/Investors/Public Shareholders (via NASDAQ IPO)

Public Shareholders (via NASDAQ IPO)

Biotech Investor · 2 portfolio companies

Portfolio
2
Combined Value
$218.8M
Focus Areas
1
Top Stage
Commercial

Investment Focus

Portfolio Companies

CompanyValuation
Burning Rock Biotech$205.9M
CytoMed Therapeutics$12.9M